[{"indications": "Indications\u00a0severe chronic hand eczema refractory\r\nto potent topical corticosteroids", "name": "ALITRETINOIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.5 Preparations for eczema and psoriasis", "13.5.1 Preparations for eczema", "Oral retinoid for eczema"], "cautions": "Cautions\u00a0avoid blood donation during treatment\r\nand for at least 1 month after stopping treatment; monitor serum lipids (more frequently in those with\r\ndiabetes, history of hyperlipidaemia, or risk factors for cardiovascular\r\ndisease)\u2014discontinue if uncontrolled hyperlipidaemia; history of depression; dry eye syndrome; interactions: Appendix 1 (retinoids)Pregnancy prevention\u00a0In women of\r\nchild-bearing potential, exclude pregnancy 1 month before treatment,\r\nup to 3 days before treatment, every month during treatment (unless\r\nthere are compelling reasons to indicate that there is no risk of\r\npregnancy), and 5 weeks after stopping treatment\u2014perform pregnancy\r\ntest in the first 3 days of the menstrual cycle. Women must practise effective contraception for at least 1 month\r\nbefore starting treatment, during treatment, and for at least 1 month\r\nafter stopping treatment. Women should be advised to use at least\r\n1 method of contraception but ideally they should use 2 methods of\r\ncontraception. Oral progestogen-only contraceptives are not considered\r\neffective. Barrier methods should not be used alone but can be used\r\nin conjunction with other contraceptive methods. Each prescription for alitretinoin should be limited to a supply\r\nof up to 30 days\u2019 treatment and dispensed within 7 days of the date\r\nstated on the prescription. Women should\r\nbe advised to discontinue treatment and to seek prompt medical attention\r\nif they become pregnant during treatment or within 1 month of stopping\r\ntreatment", "side-effects": "Side-effects\u00a0raised serum concentration of triglycerides and\r\nof cholesterol (risk of pancreatitis if triglycerides above 9\u00a0mmol/litre),\r\nflushing; headache; changes in thyroid function tests; anaemia; myalgia,\r\nraised creatine kinase, arthralgia; conjunctivitis, dry eyes (may\r\nrespond to lubricating eye ointment or tear replacement therapy)\u2014sometimes\r\ndecreased tolerance to contact lenses, eye irritation; dryness of\r\nskin and lips, cheilitis, erythema, alopecia; less commonly epistaxis, hyperostosis, ankylosing spondylitis, blurred vision,\r\ncataracts, pruritus, and asteototic eczema; rarely benign intracranial hypertension (discontinue if severe headache,\r\nnausea, vomiting, papilloedema, or visual disturbances occur) and\r\nvasculitis; also reported keratitis and impaired night vision", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201617.htm", "doses": ["adult over 18 years, 30\u00a0mg\r\nonce daily, reduced to 10\u00a0mg once daily if not tolerated; patients\r\nwith diabetes, history of hyperlipidaemia, or risk factors for cardiovascular\r\ndisease, initially 10\u00a0mg once daily, increased if necessary up to\r\nmax. 30\u00a0mg daily", "Duration of treatment 12\u201324 weeks; discontinue\r\nif no response after 12 weeks. Course may be repeated in those who\r\nrelapse. See also Pregnancy Prevention, above"], "pregnancy": "Pregnancy\u00a0avoid\u2014teratogenic; effective contraception must be\r\nused\u2014see Pregnancy Prevention above"}]